|
|
Volumn 29, Issue 11, 2011, Pages 955-957
|
|
Larger companies dominate cancer companion diagnostic approvals.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANAPLASTIC LYMPHOMA KINASE;
ANTINEOPLASTIC AGENT;
CRIZOTINIB;
INDOLE DERIVATIVE;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
PYRAZOLE DERIVATIVE;
PYRIDINE DERIVATIVE;
SULFONAMIDE;
VEMURAFENIB;
ANALYTICAL EQUIPMENT;
DRUG ANTAGONISM;
DRUG APPROVAL;
DRUG INDUSTRY;
ECONOMICS;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
NEOPLASM;
NOTE;
PROGNOSIS;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMANS;
INDOLES;
LUNG NEOPLASMS;
NEOPLASMS;
PROGNOSIS;
PROTEIN KINASE INHIBITORS;
PYRAZOLES;
PYRIDINES;
REAGENT KITS, DIAGNOSTIC;
RECEPTOR PROTEIN-TYROSINE KINASES;
SULFONAMIDES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84857752380
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1111-955 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|
